A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years
Clinical trial NCT01810393 · COMPLETED
Trial details
- NCT number
- NCT01810393
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-06-11
- Primary completion
- 2019-07-17
- Enrollment
- 114
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.